Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. LEXX

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide

Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. Strong patents covering … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study arm used a Rybelsus(R) composition processed with DehydraTECH that is compliant … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2, GLP-1-H24-2. The study aims to evaluate the company’s patented DehydraTECH(TM) technology for … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study. This marks a milestone for the company, notably since it announced its focus … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, started 2024 with a portfolio of 38 patents granted worldwide, having received ten new granted patents during 2023, the most yet in a single year. That patent portfolio, company … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment